DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

BACKGROUND: Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has demonstrated synergy in xenograft models. The aim of this study was to assess t...

Полное описание

Библиографические подробности
Главные авторы:	Gupta, A, Love, S, Schuh, A, Shanyinde, M, Larkin, J, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Collins, L, Wise, A, Asher, R, Lisle, R, Middleton, MR
Формат:	Journal article
Язык:	English
Опубликовано:	Oxford University Press 2014

Схожие документы

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
по: Gupta, A, и др.
Опубликовано: (2013)

Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
по: Gupta, A, и др.
Опубликовано: (2020)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study
по: Robert, C, и др.
Опубликовано: (2013)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
по: Robert, C, и др.
Опубликовано: (2013)

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
по: Kirkwood, J, и др.
Опубликовано: (2012)

Improved survival with MEK inhibition in BRAF-mutated melanoma.
по: Flaherty, K, и др.
Опубликовано: (2012)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
по: K. Haslett, и др.
Опубликовано: (2021-05-01)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
по: Edmund Poon, и др.
Опубликовано: (2017-08-01)

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
по: Jessie Villanueva, и др.
Опубликовано: (2013-09-01)

Immunological effects of BRAF+MEK inhibition
по: Paolo A. Ascierto, и др.
Опубликовано: (2018-09-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
по: Eva Marie Erfurth, и др.
Опубликовано: (2024-12-01)

Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib
по: Andrea Gazzin, и др.
Опубликовано: (2024-06-01)

Identification of the Major Degradation Pathways of Selumetinib
по: Tahar Sif eddine Bouchema, и др.
Опубликовано: (2022-11-01)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
по: Pacey, S, и др.
Опубликовано: (2016)

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
по: Anne L Estep, и др.
Опубликовано: (2007-12-01)

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
по: Sara Bjursten, и др.
Опубликовано: (2019-11-01)

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
по: Sarah J. Welsh, и др.
Опубликовано: (2015-03-01)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
по: Blessie Elizabeth Nelson, и др.
Опубликовано: (2023-05-01)

Effect of food on capsule and granule formulations of selumetinib
по: Sarit Cohen‐Rabbie, и др.
Опубликовано: (2022-04-01)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
по: Hui-Ju Huang, и др.
Опубликовано: (2021-06-01)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
по: Leijen, S, и др.
Опубликовано: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
по: Leijen, S, и др.
Опубликовано: (2011)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
по: Bengt Tholander, и др.
Опубликовано: (2020-10-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
по: Ken Saijo, и др.
Опубликовано: (2022-08-01)

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors
по: Anaïs Roeser, и др.
Опубликовано: (2019-11-01)

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
по: Lovisa Falkman, и др.
Опубликовано: (2024-04-01)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
по: Clare Judith Stones, и др.
Опубликовано: (2013-05-01)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
по: Jan Leipe, и др.
Опубликовано: (2019-06-01)

Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy
по: Matthew R. Kroll, и др.
Опубликовано: (2024-07-01)

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
по: Shivshankari Rajkumar, и др.
Опубликовано: (2022-04-01)

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation
по: J. Steininger, и др.
Опубликовано: (2024-08-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
по: I. V. Samoylenko, и др.
Опубликовано: (2017-11-01)

Exceptional response to rechallenge of BRAF/MEK inhibitors in patients with primary acquired resistance to targeted therapy
по: B. Ziółkowska, и др.
Опубликовано: (2024-01-01)

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
по: Michael J. Vido, и др.
Опубликовано: (2018-11-01)

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
по: Zeynep Eroglu, и др.
Опубликовано: (2016-01-01)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
по: Raphael Reinhard, MD, и др.
Опубликовано: (2018-03-01)

A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination
по: Manrose Singh, и др.
Опубликовано: (2024-08-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
по: Sivakamavalli Jeyachandran
Опубликовано: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
по: Ariane Fizazi, и др.
Опубликовано: (2024-11-01)

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study
по: Marit A. C. Vermunt, и др.
Опубликовано: (2021-08-01)